Education
About Us
Working with TipRanks
Follow Us
Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496)
:2496
Total Valuation
Wuhan YZY Biopharma Co., Ltd. Class H has a market cap or net worth of ―. The enterprise value is HK$939.43M.
Market Cap―
Enterprise ValueHK$939.43M
Share Statistics
Wuhan YZY Biopharma Co., Ltd. Class H has 111,468,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding111,468,810
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Wuhan YZY Biopharma Co., Ltd. Class H’s return on equity (ROE) is -3.20 and return on invested capital (ROIC) is -62.07%.
Return on Equity (ROE)-3.20
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-62.07%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee954.10K
Profits Per Employee-863.71K
Employee Count113
Asset Turnover0.40
Inventory Turnover5.34
Valuation Ratios
The current PE Ratio of Wuhan YZY Biopharma Co., Ltd. Class H is ―. Wuhan YZY Biopharma Co., Ltd. Class H’s PEG ratio is 0.28.
PE Ratio―
PS Ratio13.98
PB Ratio49.37
Price to Fair Value49.37
Price to FCF-14.75
Price to Operating Cash Flow-20.71
PEG Ratio0.28
Income Statement
In the last 12 months, Wuhan YZY Biopharma Co., Ltd. Class H had revenue of 107.81M and earned -97.60M in profits. Earnings per share was -0.50.
Revenue107.81M
Gross Profit85.07M
Operating Income-98.00M
Pretax Income-97.60M
Net Income-97.60M
EBITDA-86.95M
Earnings Per Share (EPS)-0.50
Cash Flow
In the last 12 months, operating cash flow was -30.34M and capital expenditures -775.00K, giving a free cash flow of -31.11M billion.
Operating Cash Flow-30.34M
Free Cash Flow-31.11M
Free Cash Flow per Share-0.28
Dividends & Yields
Wuhan YZY Biopharma Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.23
52-Week Price Change-1.44%
50-Day Moving Average5.92
200-Day Moving Average5.67
Relative Strength Index (RSI)93.93
Average Volume (3m)920.00
Important Dates
Wuhan YZY Biopharma Co., Ltd. Class H upcoming earnings date is Mar 27, 2026, TBA (Confirmed).
Last Earnings DateAug 26, 2025
Next Earnings DateMar 27, 2026
Ex-Dividend Date―
Financial Position
Wuhan YZY Biopharma Co., Ltd. Class H as a current ratio of 1.19, with Debt / Equity ratio of 417.08%
Current Ratio1.19
Quick Ratio1.17
Debt to Market Cap0.08
Net Debt to EBITDA-0.01
Interest Coverage Ratio-24.03
Taxes
In the past 12 months, Wuhan YZY Biopharma Co., Ltd. Class H has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Wuhan YZY Biopharma Co., Ltd. Class H EV to EBITDA ratio is -17.35, with an EV/FCF ratio of -14.76.
EV to Sales13.99
EV to EBITDA-17.35
EV to Free Cash Flow-14.76
EV to Operating Cash Flow-14.98
Balance Sheet
Wuhan YZY Biopharma Co., Ltd. Class H has HK$166.18M in cash and marketable securities with HK$156.66M in debt, giving a net cash position of HK$9.52M billion.
Cash & Marketable SecuritiesHK$166.18M
Total DebtHK$156.66M
Net CashHK$9.52M
Net Cash Per ShareHK$0.09
Tangible Book Value Per ShareHK$0.16
Margins
Gross margin is 100.00%, with operating margin of -90.90%, and net profit margin of -90.53%.
Gross Margin100.00%
Operating Margin-90.90%
Pretax Margin-90.53%
Net Profit Margin-90.53%
EBITDA Margin-80.65%
EBIT Margin-86.74%
Analyst Forecast
The average price target for Wuhan YZY Biopharma Co., Ltd. Class H is HK$5.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$5.50
Price Target Upside-19.47% Downside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast57.57%